Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement Post author:GHIAA Admin Post published:August 12, 2022 Post category: Continue ReadingGates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
Shionogi – GARDP, Cefiderocol License Agreement Post author:GHIAA Admin Post published:July 8, 2022 Post category: Continue ReadingShionogi – GARDP, Cefiderocol License Agreement
NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement Post author:GHIAA Admin Post published:June 29, 2022 Post category: Continue ReadingNIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
Entasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement Post author:GHIAA Admin Post published:June 7, 2022 Post category: Continue ReadingEntasis – DNDi/GARDP, Gonorrhoea Medication, Collaboration Agreement
Boston University Startup Exclusive License Template Post author:GHIAA Admin Post published:June 7, 2022 Post category: Continue ReadingBoston University Startup Exclusive License Template
Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement Post author:GHIAA Admin Post published:May 31, 2022 Post category: Continue ReadingElkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement
CSIC – MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement Post author:GHIAA Admin Post published:May 24, 2022 Post category: Continue ReadingCSIC – MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
Gates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement Post author:GHIAA Admin Post published:April 26, 2022 Post category: Continue ReadingGates Foundation – Arsanis, S. Aureus Antibody Strategic Relationship Letter Agreement
Gates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement Post author:GHIAA Admin Post published:April 25, 2022 Post category: Continue ReadingGates Foundation – Arsanis RSV Monoclonal Antibodies Funding Agreement